Metastatic colorectal cancer: ESMO Clinical Practice . . . In the case of clinical or radiological suspicion of mCRC, histological diagnosis of colorectal adenocarcinoma or related metastases should always be confirmed before administration of anticancer therapy [IV, A]
ESMO Clinical Practice Guideline: Metastatic Colorectal Cancer Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Published online: 14 April 2026 – Annals of Oncology Cremolini C, Chalabi M, Elez E, et al , on behalf of the ESMO Guidelines Committee This ESMO Clinical Practice Guideline provides recommendations and algorithms for managing metastatic colorectal cancer It covers diagnosis, molecular
Treatment of Metastatic Colorectal Cancer: ASCO Guideline PURPOSETo develop recommendations for treatment of patients with metastatic colorectal cancer (mCRC) METHODSASCO convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for clinical practice RESULTSFive
U. S. FDA Grants Full Approval to Pfizer’s BRAFTOVI . . . NEW YORK-- (BUSINESS WIRE)-- Pfizer Inc (NYSE: PFE) today announced that the U S Food and Drug Administration (FDA) has granted full approval to BRAFTOVI ® (encorafenib) in combination with cetuximab (marketed as ERBITUX ®) and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation based on results from the
Initial systemic therapy for metastatic colorectal cancer INTRODUCTION The treatment of metastatic colorectal cancer (mCRC) is evolving Many systemic therapies, including chemotherapy, immunotherapy, and targeted agents, have improved overall survival (OS) for this disease Management is also increasingly being driven by tumor biology and gene expression analysis of individual tumors
Metastatic Colorectal Cancer Treatment Options The Colorectal Cancer Alliance is a national organization committed to ending colorectal cancer within our lifetime We are your allies — a national network of passionate survivors, caregivers and advocates dedicated to helping you and your family navigate all aspects of the disease, from diagnosis and treatment to a lifetime of progression
ESMO 2026 Guideline: Redefining the Management of Metastatic . . . ESMO 2026 Guideline: Redefining the Management of Metastatic Colorectal Cancer Metastatic colorectal cancer (mCRC) represents a complex and biologically diverse disease in which treatment decisions increasingly depend on molecular characteristics, disease burden, and patient-specific factors
Mechanisms of metastatic colorectal cancer - Nature Metastatic colorectal cancer (mCRC) has a poor prognosis, and therapeutic options are limited This Review provides a comprehensive overview of the genetic and molecular underpinnings of mCRC
Metastatic Colorectal Cancer (mCRC) Education - Takeda Oncology Metastatic colorectal cancer (mCRC) can also be referred to as advanced colon cancer or stage 4 colon cancer 4 Metastases – cancer cells that break away from the original tumor, spread through the bloodstream or lymphatic system and form new tumors on different organs – are the main cause of CRC-related mortality 5,6 mCRC is a highly heterogeneous disease, meaning the disease can affect
What Is Metastatic Colorectal Cancer (mCRC)? What is metastatic colorectal cancer (mCRC)? mCRC is a stage of colorectal cancer during which the cancer has spread from the colon or rectum to other parts of the body (metastasis) It is also known as stage 4 cancer or advanced colorectal cancer Approximately 23% of people diagnosed with CRC are diagnosed after their cancer has already